Key result
This communication proposes the periprocedural use of intravenous short/ultrashort-acting β-blockers during invasive electrophysiologic procedures to prevent Takotsubo syndrome in susceptible patients.
Why the study?
Does the periprocedural use of intravenous short/ultrashort-acting β-blockers prevent Takotsubo syndrome in susceptible patients undergoing invasive electrophysiologic procedures?
Does the periprocedural use of intravenous short/ultrashort-acting β-blockers prevent Takotsubo syndrome in susceptible patients undergoing invasive electrophysiologic procedures?
This communication proposes the prophylactic use of short-acting intravenous beta-blockers during electrophysiology procedures to prevent Takotsubo syndrome in susceptible patients.
This communication proposes the periprocedural use of intravenous short/ultrashort-acting β-blockers, in the course of invasive electrophysiologic procedures in general, to prevent the emergence of Takotsubo syndrome in seemingly susceptible patients. Such infusions could be stopped with impunity if the use of epinephrine or isoproterenol is deemed necessary as part of the implemented electrophysiology protocol or if side effects arise.
No takes yet. Share an insight, caveat, or question.
John E. Madias (2025) studied Takotsubo syndrome. Intravenous short/ultrashort-acting β-blockers was evaluated on Emergence of Takotsubo syndrome. This communication proposes the periprocedural use of intravenous short/ultrashort-acting β-blockers during invasive electrophysiologic procedures to prevent Takotsubo syndrome in susceptible patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: